Cannabidiol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319869

CAS#: 13956-29-1

Description: Cannabidiol, also know as CBD, is a major phytocannabinoid, accounting for up to 40% of the plant's extract. CBD is considered to have a wider scope of potential medical applications than tetrahydrocannabinol (THC). Cannabidiol has been listed in the European Commission Cosmetics Ingredient Database with four functional claims: antioxidant, antiseborroeic, skin conditioning, and skin protecting.


Price and Availability

Size
Price

10mg
USD 180
Size
Price

50mg
USD 400
Size
Price

Cannabidiol purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319869
Name: Cannabidiol
CAS#: 13956-29-1
Chemical Formula: C21H30O2
Exact Mass: 314.2246
Molecular Weight: 314.469
Elemental Analysis: C, 80.21; H, 9.62; O, 10.18


Synonym: Cannabidiol, CBD,

IUPAC/Chemical Name: 2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol

InChi Key: QHMBSVQNZZTUGM-ZWKOTPCHSA-N

InChi Code: InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1

SMILES Code: OC1=CC(CCCCC)=CC(O)=C1[C@@H]2C=C(C)CC[C@H]2C(C)=C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Feb 1. pii: S1043-6618(16)00039-6. doi: 10.1016/j.phrs.2016.01.033. [Epub ahead of print] Review. PubMed PMID: 26845349.

2: Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse. 2015 May 21;9:33-8. doi: 10.4137/SART.S25081. eCollection 2015. Review. PubMed PMID: 26056464; PubMed Central PMCID: PMC4444130.

3: Silva TB, Balbino CQ, Weiber AF. The relationship between cannabidiol and psychosis: A review. Ann Clin Psychiatry. 2015 May;27(2):134-41. Review. PubMed PMID: 25954940.

4: Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7. Review. PubMed PMID: 25703248.

5: Fowler CJ. Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clin Pharmacol Ther. 2015 Jun;97(6):587-96. doi: 10.1002/cpt.84. Epub 2015 May 2. Review. PubMed PMID: 25669486.

6: Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review. PubMed PMID: 25667194.

7: Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response. Epilepsy Behav. 2014 Dec;41:277-82. doi: 10.1016/j.yebeh.2014.08.135. Epub 2014 Oct 1. Review. PubMed PMID: 25282526.

8: McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review. PubMed PMID: 25257544; PubMed Central PMCID: PMC4301686.

9: de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953-60. Review. PubMed PMID: 24923339.

10: Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review. PubMed PMID: 24854329; PubMed Central PMCID: PMC4707667.

11: Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review. PubMed PMID: 24671907.

12: Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15. Review. PubMed PMID: 24309088.

13: Niesink RJ, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review. PubMed PMID: 24137134; PubMed Central PMCID: PMC3797438.

14: Takeda S. [Medicinal chemistry and pharmacology focused on cannabidiol, a major component of the fiber-type cannabis]. Yakugaku Zasshi. 2013;133(10):1093-101. Review. Japanese. PubMed PMID: 24088353.

15: Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review. PubMed PMID: 23108553; PubMed Central PMCID: PMC3481531.

16: Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013 May;27(5):633-6. doi: 10.1002/ptr.4781. Epub 2012 Jul 20. Review. PubMed PMID: 22815234.

17: Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese. PubMed PMID: 22729452.

18: Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012;18(32):5131-40. Review. PubMed PMID: 22716160.

19: Roser P, Haussleiter IS. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des. 2012;18(32):5141-55. Review. PubMed PMID: 22716153.

20: Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18(32):4966-79. Review. PubMed PMID: 22716148.